Agostino Chiaravalloti1,2, Anna Elisa Castellano3, Maria Ricci4, Gaetano Barbagallo5, Pasqualina Sannino3, Francesco Ursini6, Georgios Karalis7, Orazio Schillaci7,3. 1. Department of Biomedicine and Prevention, University Tor Vergata, Viale Oxford 81, 00133, Rome, Italy. agostino.chiaravalloti@gmail.com. 2. IRCCS Neuromed, Pozzilli, Italy. agostino.chiaravalloti@gmail.com. 3. IRCCS Neuromed, Pozzilli, Italy. 4. Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy. 5. Institute of Neurology, University Magna Graecia of Catanzaro, Catanzaro, Italy. 6. Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy. 7. Department of Biomedicine and Prevention, University Tor Vergata, Viale Oxford 81, 00133, Rome, Italy.
Abstract
PURPOSE: The present study was aimed to investigate the relationships between dysfunction of cortical glucose metabolism as detectable by means of 2-deoxy-2-[18F]fluoro -D-glucose ([18F]FDG) positron emission tomography/x-ray computed tomography (PET/CT) and amyloid burden as detectable by means of 4-{(E)-2-[4-(2-{2-[2-[18F]fluoroethoxy]ethoxy}ethoxy)phenyl]vinyl}-N-methylaniline (florbetaben; [18F]FBB) in a group of patients affected by Alzheimer's disease (AD). PROCEDURES: We examined 38 patients newly diagnosed with AD according to the NINCDS-ADRDA criteria. All the subjects underwent a PET/CT scan using both [18F]FDG and [18F]FBB with an average interval of 1 month. We used statistical parametric mapping (SPM8) implemented in Matlab R2012b and WFU pickatlas for the definition of a region of interest (ROI) mask including the whole cortex. These data were then normalized on the counts of the cerebellum and then used for a regression analysis on [18F]FDG scans in SPM. Furthermore, 58 control subjects were used as control group for [18F]FDG PET/CT scans. RESULTS: SPM analysis in AD patients showed a significant negative correlation between [18F] FBB and [18F] FDG uptake in temporal and parietal lobes bilaterally. Of note, these areas in AD patients displayed a marked glucose hypometabolism compared to control group. CONCLUSIONS: Combined imaging with [18F]FBB and [18FFDG shows that amyloid burden in the brain is related to cortical dysfunction of temporal and parietal lobes in AD.
PURPOSE: The present study was aimed to investigate the relationships between dysfunction of cortical glucose metabolism as detectable by means of 2-deoxy-2-[18F]fluoro -D-glucose ([18F]FDG) positron emission tomography/x-ray computed tomography (PET/CT) and amyloid burden as detectable by means of 4-{(E)-2-[4-(2-{2-[2-[18F]fluoroethoxy]ethoxy}ethoxy)phenyl]vinyl}-N-methylaniline (florbetaben; [18F]FBB) in a group of patients affected by Alzheimer's disease (AD). PROCEDURES: We examined 38 patients newly diagnosed with AD according to the NINCDS-ADRDA criteria. All the subjects underwent a PET/CT scan using both [18F]FDG and [18F]FBB with an average interval of 1 month. We used statistical parametric mapping (SPM8) implemented in Matlab R2012b and WFU pickatlas for the definition of a region of interest (ROI) mask including the whole cortex. These data were then normalized on the counts of the cerebellum and then used for a regression analysis on [18F]FDG scans in SPM. Furthermore, 58 control subjects were used as control group for [18F]FDG PET/CT scans. RESULTS: SPM analysis in ADpatients showed a significant negative correlation between [18F] FBB and [18F] FDG uptake in temporal and parietal lobes bilaterally. Of note, these areas in ADpatients displayed a marked glucose hypometabolism compared to control group. CONCLUSIONS: Combined imaging with [18F]FBB and [18FFDG shows that amyloid burden in the brain is related to cortical dysfunction of temporal and parietal lobes in AD.
Authors: Paul S Aisen; Ronald C Petersen; Michael C Donohue; Anthony Gamst; Rema Raman; Ronald G Thomas; Sarah Walter; John Q Trojanowski; Leslie M Shaw; Laurel A Beckett; Clifford R Jack; William Jagust; Arthur W Toga; Andrew J Saykin; John C Morris; Robert C Green; Michael W Weiner Journal: Alzheimers Dement Date: 2010-05 Impact factor: 21.566
Authors: Elisabeth Klupp; Timo Grimmer; Masoud Tahmasian; Christian Sorg; Igor Yakushev; Behrooz H Yousefi; Alexander Drzezga; Stefan Förster Journal: J Nucl Med Date: 2015-02-12 Impact factor: 10.057
Authors: Ryuichi Takahashi; Kazunari Ishii; Kazumasa Yokoyama; EmptyYN Y For The Alzheimer S Disease Neuroimaging Initiative Journal: Curr Alzheimer Res Date: 2017 Impact factor: 3.498
Authors: John T O'Brien; Michael J Firbank; Christopher Davison; Nicky Barnett; Claire Bamford; Cam Donaldson; Kirsty Olsen; Karl Herholz; David Williams; Jim Lloyd Journal: J Nucl Med Date: 2014-11-05 Impact factor: 10.057